Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Business Wire
– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure (SBS-IF) accepted as late-breaker oral presentation on May 21 at 10:30 am ET –– Findings from the STARS Nutrition Study in SBS-IF will be highlighted in poster presentations –– Additional posters will focus on linaclotide, irritable bowel syndrome with constipation and functional constipation – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting. DDW is held from May 18-21, 2024, in Washington, D.C.SBS-IF, a rare chronic debilitating malabsorptive condition in which patients are dependent on PS, affects an estimated 18,000 adult patients in the U.S., Europe, a
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- US$16.33: That's What Analysts Think Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Is Worth After Its Latest Results [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Craig Hallum from $18.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals Reports First Quarter 2024 Results [Yahoo! Finance]Yahoo! Finance
IRWD
Earnings
- 5/9/24 - Miss
IRWD
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/25/24 - Form ARS
- IRWD's page on the SEC website